Loading...
Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model
Benedetti, E Antonosante, A d'Angelo, M Cristiano, L Galzio, R Destouches, D Florio, TM Dhez, AC Astarita, C Cinque, B
Benedetti, E
Antonosante, A
d'Angelo, M
Cristiano, L
Galzio, R
Destouches, D
Florio, TM
Dhez, AC
Astarita, C
Cinque, B
Citations
Altmetric:
Genre
Journal Article
Date
2015-01-01
Advisor
Committee member
Group
Department
Subject
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
10.18632/oncotarget.5990
Abstract
Nucleolin (NCL) is highly expressed in several types of cancer and represents an interesting therapeutic target. It is expressed at the plasma membrane of tumor cells, a property which is being used as a marker for several human cancer including glioblastoma. In this study we investigated targeting NCL as a new therapeutic strategy for the treatment of this pathology. To explore this possibility, we studied the effect of an antagonist of NCL, the multivalent pseudopeptide N6L using primary culture of human glioblastoma cells. In this system, N6L inhibits cell growth with different sensitivity depending to NCL localization. Cell cycle analysis indicated that N6L-induced growth reduction was due to a block of the G1/S transition with down-regulation of the expression of cyclin D1 and B2. By monitoring autophagy markers such as p62 and LC3II, we demonstrate that autophagy is enhanced after N6L treatment. In addition, N6L-treatment of mice bearing tumor decreased in vivo tumor growth in orthotopic brain tumor model and increase mice survival. The results obtained indicated an antiproliferative and pro-autophagic effect of N6L and point towards its possible use as adjuvant agent to the standard therapeutic protocols presently utilized for glioblastoma.
Description
Citation
Citation to related work
Impact Journals, LLC
Has part
Oncotarget
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu